3
Announcements
Trials
Browse
Landscape
Sponsor
Conditions
Breast Neoplasms
10
Salivary Gland Neoplasms
2
Ovarian Neoplasms
2
Multiple Myeloma
2
Lymphoma
2
Hematologic Neoplasms
2
Endometrial Neoplasms
2
Colorectal Neoplasms
2
Brain Neoplasms
2
Uterine Neoplasms
1
Uterine Cervical Neoplasms
1
Urinary Bladder Neoplasms
1
Triple Negative Breast Neoplasms
1
Thyroid Neoplasms
1
Stomach Neoplasms
1
Solid Tumors
1
Rectal Neoplasms
1
Prostatic Neoplasms
1
Pathologic Complete Response
1
Pancreatic Neoplasms
1
Neoplasms
1
Neoplasm, Residual
1
Neoplasm Metastasis
1
Melanoma
1
Lung Neoplasms
1
Hemangiosarcoma
1
HER2-positive Metastatic Breast Cancer
1
HER2-positive Breast Cancer
1
HER2-Positive Primary Breast Cancer
1
Glioma
1
Interventions
Cyclophosphamide
27
fludarabine
19
Dexamethasone
18
pembrolizumab
12
Rituximab
12
Etoposide
11
venetoclax
10
pomalidomide
9
Gemcitabine
9
Lenalidomide
8
fludarabine phosphate
7
daratumumab
7
Bortezomib
7
glofitamab
6
carfilzomib
6
Vincristine
6
obinutuzumab
5
Temozolomide
5
Prednisone
5
Nivolumab
5
Immunotherapy, Adoptive
5
Doxorubicin
5
Cytarabine
5
Cisplatin
5
Calcium Dobesilate
5
selinexor
4
cemiplimab
4
Carboplatin
4
Azacitidine
4
zanubrutinib
3
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
0 trials
Recent
Start date
Enrollment
Recurrence
×
Ado-Trastuzumab Emtansine
×
90 days
×
Clear all
No trials found.